Prototypical Stressors

Showing 551 to 575 of 855 Prototypical Stressors

ID	Prototypical Stressor Name	Associated Chemical(s): Name, CAS-RN, DTXSID	Associated AOPs

127	Nocodazole	Nocodazole, CAS-RN: 31430-18-9, DTXSID9031800	106: Chemical binding to tubulin in oocytes leading to aneuploid offspring
436	None		None
275	NonSteroidal Anti-Inflammatory Drugs (NSAID)		217: Gastric ulcer formation
797	Norepinephrine		554: β-adrenergic receptor agonists leading to arrhythmias.
390	Norfloxacin	Norfloxacin, CAS-RN: 70458-96-7, DTXSID7037680	144: Endocytic lysosomal uptake leading to liver fibrosis
234	norfluoxetine		203: 5-hydroxytryptamine transporter inhibition leading to decreased reproductive success and population decline
297	NSAID (Nonsteroidal anti-inflammatory drug) inhibits PTGS1		227: NSAID induced PTGS1 inactivation to gastric ulcer
298	NSAID (Nonsteroidal anti-inflammatory drug) inhibits PTGS2		228: NSAID induced PTGS2 inactivation to gastric ulcer
226	o-methyl-serine dodecylamide hydrochloride (MSDH)		144: Endocytic lysosomal uptake leading to liver fibrosis
42	Ochratoxin A	Ochratoxin A, CAS-RN: 303-47-9, DTXSID7021073	None
424	Oligomycin	Oligomycin, CAS-RN: 1404-19-9, DTXSID7040570	None
399	Oligomycin A, Aurovertin		None
43	Organophosphates	Parathion, CAS-RN: 56-38-2, DTXSID7021100 Soman, CAS-RN: 96-64-0, DTXSID2031906	10 AOPs 405: Organo-Phosphate Chemicals induced inhibition of AChE leading to impaired cognitive function 450: Inhibition of AChE and activation of CYP2E1 leading to sensory axonal peripheral neuropathy and mortality 490: Co-activation of IP3R and RyR leads to reduced IQ and increased socio-economic burden through non-cholinergic mechanisms 543: Inhibition of neuropathy target esterase leading to delayed neuropathy via lysolecithin cell membrane integration 544: Inhibition of neuropathy target esterase leading to delayed neuropathy via increased inflammation 552: Inhibiton of L-Type Calcium Channels leading to heart failure via QT interval prolongation and Torsades de Pointes (TdP) 555: Inhibition, Ether-a-go-go (ERG) Voltage-Gated Potassium Channel leading to heart failure 556: Decreased Na/K ATPase activity leading to heart failure 560: Inhibition of Funny current (If) leading to Arrhythmias 562: HCN Channel Inhibition leading to Arrhythmias
577	Osilodrostat(LCI699)		349: Inhibition of 11β-hydroxylase leading to decresed population trajectory
453	Other DNA damaging agents		2 AOPs 294: Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer 293: Increased DNA damage leading to increased risk of breast cancer
714	Other heavy metal effects		None
715	Other heavy metals		None
805	Ouabain		556: Decreased Na/K ATPase activity leading to heart failure
829	Oxadiazon	Oxadiazon, CAS-RN: 19666-30-9, DTXSID3024239	561: Aromatase induction leading to estrogen receptor alpha activation via increased estradiol
857	Oxaliplatin	Oxaliplatin, CAS-RN: 61825-94-3, DTXSID0036760	472: DNA adduct formation leading to kidney failure
184	Oxaprozin	Oxaprozin, CAS-RN: 21256-18-8, DTXSID1045118	None
516	oxidative stress		None
744	Oxyclozanide	Oxyclozanide, CAS-RN: 2277-92-1, DTXSID50177312	263: Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased cell proliferation
90	Oxytetracycline hydrochloride	Oxytetracycline hydrochloride, CAS-RN: 2058-46-0, DTXSID5021097	None
655	Ozone	Ozone, CAS-RN: 10028-15-6, DTXSID0021098	2 AOPs 411: Oxidative stress Leading to Decreased Lung Function 424: Oxidative stress Leading to Decreased Lung Function via CFTR dysfunction